Logo

Janssen Discontinues its 2018 License Agreement with Argenx for Cusatuzumab

Share this

Janssen Discontinues its 2018 License Agreement with Argenx for Cusatuzumab

Shots:

  • The discontinuation is based on Janssen's review of all available cusatuzumab data and in consideration of the evolving SOC for AML. Argenx regain its WW rights to cusatuzumab from Cilag
  • The P-Ib ELEVATE interim data will support the development of the anti-CD70 Ab in AML- whereas argenx plans to evaluate options to enable a path forward
  • Janssen will work with argenx to transition the cusatuzumab program back to argenx. Following the termination- argenx can elect that Janssen operationally support the treatment and follow-up of patients enrolled in ongoing cusatuzumab clinical studies

Ref: Janssen | Image: Janssen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions